Cholangiocarcinomas Recruiting Phase 2 Trials for Nivolumab (DB09035)

Also known as: Cholangiocarcinoma / Cholangiocarcinoma NOS / Cholangiocarcinoma of biliary tract

IndicationStatusPhase
DBCOND0051818 (Cholangiocarcinomas)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02834013Nivolumab and Ipilimumab in Treating Patients With Rare TumorsTreatment
NCT03250273A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic AdenocarcinomaTreatment